| Document |
Document Title |
|
WO/2003/066032A1 |
There is provided a pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of for...
|
|
WO/2003/066036A1 |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long−acting β2−adrenoreceptor agon...
|
|
WO/2003/066656A1 |
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121 having u...
|
|
WO/2003/066024A1 |
There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) or a solvate thereof.
|
|
WO/2003/064445A1 |
A compound of formula (I): wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents a 5 membered heterocyclic aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl group...
|
|
WO/2003/051903A1 |
A compound represented by the general formula (I): (I) (wherein R1 represents lower alkyl&semi X represents oxygen or methylene&semi m is an integer of 1 to 10&semi and n is an integer of 0 to 5) or a salt or ester thereof&semi a medicin...
|
|
WO/2003/047329A2 |
A method for producing a 6a-fluorinated corticosteroid or derivative thereof by reacting a17-hydroxy-21-ester epoxide of Formula (II) with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6a-fluorinate...
|
|
WO/2003/029268A1 |
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the fun...
|
|
WO/2003/024943A2 |
The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazo...
|
|
WO/2002/100878A1 |
A process for preparing flumethasone (6a,9a-diffluoro-11$g(b),17a,21-trihydroxy-16a-methyl-pregna
-1,4-diene-3,20-dione), fulmethasone 21-acetate or its 17-carboxyl androsten analogue which process comprises reacting a compound of formul...
|
|
WO/2002/089814A1 |
17-Methylene-androstan-3α-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methyleneandrost-4-en-3α-o...
|
|
WO/2002/072108A1 |
The invention relates to the use of corticosteroids and fluitcasone propionate in particular for the treatment of diseases which may be ameliorated by enhancement of epithelial/matrix adhesion.
|
|
WO/2002/036606A1 |
This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which compri...
|
|
WO/2002/036106A2 |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
WO/2002/014343A1 |
The present invention relates to a novel use of bufadienolide derivatives, as such or in the form of pharmaceutical compositions, for immunomodulation, especially for immunosuppression, for antiinflammatory and/or for antitumor action, a...
|
|
WO/2002/008243A1 |
The present invention relates inter alia to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).
|
|
WO/2002/000679A2 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
|
|
WO/2001/081328A2 |
The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazo...
|
|
WO/2001/066562A1 |
Steroid derivatives from which various estran derivatives (estran-3-O-sulfamate derivatives serving as an inhibitor of estrogen sulfatase producing estrogen which is a causative factor of estrogen-dependent mammary cancer, mammalian ster...
|
|
WO/2001/040253A2 |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R?1¿ is H or together with R?3¿ forms a $g(b)-epoxide or R?1¿ is absent if there is a 5-10 or 4-5 double bond; R?2¿ is (C¿1?-C¿5?)alkyl or C...
|
|
WO/2001/032680A2 |
The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R?1¿, R?2¿, R?3¿, R?6¿, R?7¿, R?8¿, R?9¿, R?11¿, R?11"¿, R?14¿, R?15¿, R?15"¿, R?16¿, R?17¿ and R?17"¿ have the meaning cited in t...
|
|
WO/2001/027133A1 |
The process of the present invention transforms a steroidal ketone of formula (III) to androst-4-en-17$g(b)-carboxylic acid (IV) by reaction with K¿2?SO¿5?•KHSO¿4?•K¿2?SO¿4?.
|
|
WO/2001/016601A1 |
Disclosed is a method for identifying a subunit specific modulator of the N-methyl-D-aspartate (NMDA) receptor. The method involves providing a plurality of NMDA receptors which differ in their subunit identity. The receptors are contact...
|
|
WO/2000/066611A1 |
Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.
|
|
WO/2000/056757A1 |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
WO/2000/053619A1 |
The disclosed invention relates to the unexpected finding of steroids for use as androgens which are characterized by a configuration opposite to that of natural steroids, viz. 14$g(a), 17$g(b). These steroids according to the invention ...
|
|
WO/2000/032177A2 |
The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the 'compou...
|
|
WO/2000/032201A2 |
The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the 'compou...
|
|
WO/2000/032176A2 |
The invention provides the use of 17-ketosteroid compounds, e.g., 16$g(a)-bromoepiandrosterone, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collec...
|
|
WO/1999/032127A1 |
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
|
|
WO/1999/025359A1 |
The invention provides a process for the sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or...
|
|
WO/1999/003503A1 |
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steroid are disclosed.
|
|
WO/1999/001467A2 |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
WO/1998/055498A1 |
The invention relates to 17$g(b)-allyloxy(thio)alkyl-androstane derivatives having general formula (I) wherein R�1? is (H, OR), (H, OSO�3?H) or NOR; with R being H, (C�1-6?)alkyl or (C�1-6?)acyl; each of R�2? and R�3? is inde...
|
|
WO/1998/032718A1 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
WO/1998/018429A2 |
A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of formula (I) wherein: R?1� is hydrogen or alkyl; A, B, D, E, G, R?2� and R?3� each a...
|
|
WO/1998/014194A1 |
The invention relates to a method of alleviating the symptoms of anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The st...
|
|
WO/1998/009935A1 |
A process for preparing a compound having structure (I) wherein n is an integer from 1-5; each of R�1? and R�2? independently is optionally substituted C�1?-C�6? alkyl; each of W and X is independently hydrogen or C�1?-C�6? a...
|
|
WO/1998/003207A1 |
The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor...
|
|
WO/1998/002450A2 |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
WO/1997/042214A1 |
The invention provides new androstene derivatives having anti-inflammatory activity, pharmaceutical compositions containing them, and methods of administering them to warm-blooded animals in the treatment of inflammation. The active comp...
|
|
WO/1997/024365A1 |
Compounds of the androstane series are described having general formula (I) and solvates thereof, in which R1 represents O, S or NH; R2 individually represents OC(=O)C1-6 alkyl; R3 individually represents hydrogen, methyl (which may be i...
|
|
WO/1997/001346A1 |
A cosmetic or pharmaceutical and particularly dermatological composition including, as the active ingredient, an extract of plants of genus Filicium, and particularly an extract of plants of species Filicium decipiens, preferably in an a...
|
|
WO/1996/011939A1 |
A process for providing novel compounds of formula (I), that are useful as 6-azaadrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of formula (II) wherein, R1 and R2 represent: i) indepedently H ...
|
|
WO/1996/011206A1 |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
WO/1996/010032A1 |
The invention relates to estrene steroid, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. The figure...
|
|
WO/1996/010031A1 |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
|
|
WO/1996/003422A1 |
The present invention provides compounds of formula (I) wherein the symbol --- represents a single or a double bond; R is a hydrogen atom or a C1-C4 alkyl group; A is a single bond or a straight or branched C1-C6 alkylene chain; B is a s...
|
|
WO/1996/003420A1 |
The present invention provides a compound of formula (I), wherein A is a bond or a straight or branched C1-C6 alkylene chain; W is a group -R1, -OR2, -NR3R4 or (a) wherein: Y is oxygen or sulphur; R1, R2 and R4 are: a C1-C10 alkyl group,...
|
|
WO/1996/000230A1 |
The present invention relates to a process for the preparation and manufacture of 3-amino-substituted glycosylated bile acid derivatives. Novel intermediates and related compounds are also disclosed. In particular, the present invention ...
|
